Choose your language:


ACN 616 806 574
Haixi Pharmaceuticals Prospectus


By accessing the electronic Replacement Prospectus, you agree to and acknowledge reading these terms.  If you would like us to send you a copy of the Replacement Prospectus and an Application Form, please contact the information line by telephone on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) during the period in which the offer for shares remains open and a copy will be sent to you free of charge.

1. Prospectus

Haixi Pharmaceutical International Holdings Limited (ACN 616 806 574) (Company) lodged a Replacement Prospectus dated 19 July 2017 (Replacement Prospectus) with the Australian Securities and Investments Commission (ASIC). The Replacement Prospectus replaces the original prospectus which was dated 6 July 2017 (Original Prospectus).  On 17 August 2017, the Company issued and lodged with ASIC, a supplementary prospectus under which the closing date of the offer is extended to 29 September 2017 (Supplementary Prospectus) The electronic copy of the Replacement Prospectus and Supplementary Prospectus (together the Prospectus) available on this website are substantially faithful to the copies lodged with ASIC.  The Prospectus contains details required by investors to acquire fully paid ordinary shares in the Company (Offer Shares) under the Prospectus.

The Replacement Prospectus supplemented by the Supplementary Prospectus, replaces the Original Prospectus. In accordance with Chapter 6D of the Corporations Act, the Original Prospectus was subject to an Exposure Period of 7 days from the date of lodgment of the Original Prospectus with ASIC.  This period was extended by ASIC for a further period of 7 days.

2. Important information

This notice does not form part of the Prospectus.  You must read it before you attempt to access the electronic version of the Prospectus on this website and indicate your agreement or otherwise at the bottom of this notice.

The Prospectus is an important document that should be read in its entirety.  Potential investors should read the entire Prospectus and, in particular, in considering the prospects for the Company, investors should consider the risk factors that could affect the performance of the Company.  Investors should carefully consider these factors in light of their personal circumstances (including financial and taxation issues) and seek professional advice from a licensed investment adviser.  Neither ASIC nor the Australian Stock Exchange Limited take any responsibility for the contents of the Prospectus or the investment to which it relates.  The Prospectus expires on 19 August 2018.  No Offer Shares will be issued on the basis of the Prospectus after that expiry date.

3. Persons to whom the offer is available

The electronic Prospectus on this Website must only be accessed from within Australia.  If the electronic Prospectus is accessed by a person from outside Australia, it should not be downloaded or printed, nor should any application be made by that person for Offer Shares in the Company, unless the Offer Shares have been offered to an investor in any jurisdiction where to do so would not be in breach of the securities law requirements of the relevant jurisdiction.

No action has been taken to register or qualify the Prospectus, the Offer Shares or the Offer in any jurisdiction outside Australia.  The Prospectus does not constitute an offer of shares in any jurisdiction where, or to any persons to whom, it would be unlawful to issue this Prospectus or to make an offer of Offer Shares.  In particular, the Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (US Securities Act) and may not be offered or sold in the United States except in transaction exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.

The distribution of this Prospectus outside of Australia may be restricted by law and persons who come into possession of it should seek advice and observe any such restrictions.  It is the responsibility of any applicant outside Australia to ensure compliance with all laws of any country relevant to that applicant’s jurisdiction.  Eligible shareholders who are nominees, trustees or custodians are therefore advised to seek independent advice as to how they should proceed.

4. Application for Offer Shares

Applications for Offer Shares may only be made by completing and lodging the Application Form attached to or accompanied by a paper copy of the Prospectus in accordance with the directions specified in the Prospectus.

The Corporations Act 2001 (Cth) (Corporations Act) prohibits any person from distributing to any other person an Application Form unless it is attached to a paper copy of the Prospectus or accompanies a complete and unaltered version of the electronic Prospectus.


The information on this website is provided for informational purposes only and subject to change without notice.  Nothing contained on this website or in the Prospectus constitutes investment, legal, business, taxation or other advice, nor is it to be relied on in making an investment in the Offer Shares.  The information on this website and in the Prospectus does not take into account your investment objectives, financial situation or particular needs.

Subject to the terms contained in this notice, an electronic copy of the Prospectus may be viewed or downloaded. You should ensure that any copy you view or print is complete.

I confirm have read and understood this Notice and agree to the terms and conditions above.

By downloading the Prospectus you acknowledge that you have accessed and understood the BlueMount Capital (Sydney) Pty Ltd Financial Services Guide (which can be accessed here).

Download Now!